Etoposide (4-6-demethylepipodophyllotoxin-9-(4-6-0-ethylidene-B-D-glucopyranoside) is being used increasingly in the treatment of malignancy (Cavilli et al., 1978 ., Radice et al., 1979 ., Newlands & Bagahawe, 1980) and is also toxic towards some experimental tumours (D'Incali et al., 1981) and cell lines (Huang et al., 1973; Rivera et al., 1975; Loike & Horwitz, 1976; Cavilli et al., 1978) . Etoposide is a derivative of naturally occuring podophyllotoxin and exerts its cytotoxic effect by several mechanisms including inhibition of the S and G2 phases of the cell cycle (Grieder et al., 1974; Misra & Roberts, 1975; Krishan et al., 1980) . Etoposide produces single and double-strand breaks in the DNA molecules as well as damaging nucleic acid-protein cross-links (Wozniak & Ross, 1983) . In common with related drugs it also inhibits the uptake of nucleotides into the cell possibly by the inhibition of macromolecular synthesis. (Grieder et al., 1974; Wozniak and Ross, 1983) . Recent studies (Yalowich & Goldman, 1984) suggest that etoposide inhibits both the uptake of nucleotides into the cell and subsequent incorporation into DNA. This property is not shared by podophyllotoxin.
More recently etoposide has been used in high doses with autologous bone marrow transplantation (Wolff et al., 1983; Littlewood et al., 1985) . In these circumstances it is clearly important that reinfusion is delayed until plasma concentrations are below levels which are toxic towards the stem cell population. Pharmacokinetic studies using radioactively labelled etoposide indicate that the clearance half-life is from 5.7 to 11.5 h. (Allen & Creaven, 1975; D'Incali et al., 1981; Evans et al., 1982) . Recent studies using HPLC (Littlewood et al., 1985) suggest a slower clearance and that an appreciable period is required for complete clearance of the drug. To date there are no data relating plasma concentrations to bone marrow toxicity. We examined the effects of etoposide on the human CFU-GM population in vitro in order to obtain an indication of the sensitivity of the bone marrow to the concentrations of the drug that have been measured in plasma. Etoposide is known to bind strongly to albumin (Allen & Creaven, 1975) Human serum albumin (HSA) (Fraction V Sigma) and bovine serum albumin (BSA) (Armour Pharmaceutical Company) solutions were prepared in water. The pH was adjusted to 7.4 and the osmolality to 280mosmolkg-1 using the Osmomat 030 osmometer (Gonotext), before sterilisation by filtration through a 0.22,um Millipore filter.
All assays were performed in duplicate and are the results of from 4 to 5 experiments. Sensitivity to etoposide was quantitated in terms of the concentration giving 50% survival of the cells (D50). This concentration was the mean value derived from all the experiments. Results are expressed as the mean value +s.e. and significance tested using Students t-test.
Results
The mean number of CFU-GM in the bone marrow preparations used in this study was 198+124 (s.d.) (range 84-428) per 200,000 mononuclear cells plated. This figure is within the range of values obtained in this laboratory for similar bone marrow preparations from a large number of normal subjects. Colonies obtained after 7 days incubation are mainly granulocytic (>80%) the remainder are largely mixed granulocytic-monocytic with a small number of wholly monocytic colonies. Figure 1 shows the effect of etoposide on CFU-GM growth. There was a simple log-linear (0) and cluster-forming (0) CFU-GM. Incubation was for 7 days in the soft agar assay system with human placenta conditioned medium as a source of colony stimulating factor. relationship between drug concentration and CFU-GM with a 50% survival (D50) at a mean drug concentration of 0.0098+0.0017yugml-1. Clusterforming CFU-GM were less sensitive to the drug with a D50 value of 0.075 +0.02 pgml-1.
The effect of BSA on the cytotoxicity of etoposide towards CFU-GM is illustrated in Figure 2 . Etoposide was present at a concentration of 0.018 and 0.036pgml-1 and BSA at increasing concentrations up to 40mgml-1. Results are expressed as a percentage of the control value for cultures also containing BSA. In the absence of BSA the percentage of CFU-GM present in the cultures containing 0.018 pgml-1 of etoposide was 28 and 5% in the presence of 0.036 pg ml -' etoposide.
There was a marked increase in colony number with increasing BSA up to a plateau concentration of -20 mg ml-1. This increase was -10 fold at the higher drug concentration and -2 fold at the lower concentration. Subsequent experiments using serum albumin preparations have been performed at a concentration of 25mg ml -1, this being sufficiently high to afford maximum protection over the range of etoposide used in these studies without incuring the practical difficulties of preparing accurate solutions of albumin at high concentration. When incorporated into the assay system at this concentration (Figure 3 ) marked protection of the CFU-GM population was observed. Very little inhibition of CFU-GM growth was found at concentrations below 0.01 pg ml -1, probably (0) (Littlewood et al., 1985) . Current evidence suggests that etoposide is largely effective during the S and G2 phases of the cell cycle though the mode of action may be complex (Stahelin, 1970; Drewinko and Barlogie, 1976; Krishan et al., 1983) . The response of the CFU-GM population towards etoposide showed a simple relationship as might be expected considering that colony formation takes place by virtue of cell division induced by the action of CSA. The lower sensitivity of the cluster-forming CFU (Table I ) reflects the lower level of proliferative capacity of these progenitors.
The effect of serum albumin on the sensitivity of the CFU-GM to etoposide is both interesting and important. The binding of cytotoxic drugs to protein influences their in vivo action but there has not been any previous attempt to evaluate this effect in vitro using an assay for myeloid progenitor cells. Etoposide is strongly bound to human serum albumin with -94% of the drug being bound at typical plasma concentrations (Allen & Craven, 1975) . For reasons described in the text serum albumin preparations were present in the assay at a concentration of 25 mg ml -1. The contribution made by calf serum amounted to -6 mg ml -1. These combined values are slightly less than normal serum albumin concentration of 34-45 mg ml-1. Increasing the albumin concentration further did not affect the response of the progenitor cells to etoposide over the range of drug concentration employed in these experiments. In the absence of added serum albumin the CFU-GM population is sensitive to very low concentrations of etoposide when presumably most of the drug is present in the free form. In the presence of added BSA a ten-fold higher concentration of drug is necessary to elicit a reduction of CFU-GM number although because of the greater slope of the dose response curve the D50 concentration was increased only some 4.5 fold. The effect of HSA was even more marked resulting in a decrease of only 15% at an etoposide concentration of 0.15 jg ml 1.
The binding of etoposide to albumin therefore plays a significant role in the interpretation of the pharmacokinetic data available on etoposide. The increase in D50 concentration with HSA agrees well with the protein binding data suggesting 6% free drug in the plasma. The greater efficacy of HSA compared to BSA agrees with equilibrium dialysis data showing a greater affinity of HSA for etoposide (Littlewood, unpublished data) .
These data provide a much clearer picture of the relationship between plasma concentrations of etoposide and the effect on the granulomonocytic progenitor cells. The data can be used as a guide to the plasma levels of drugs which are necessary to achieve a cytotoxic effect on the marrow and secondly as a guide to the maximum plasma levels that can be tolerated prior to reinfusion of bone marrow during autologous bone marrow transplantation.
